NXGL (NexGel) Debt-to-EBITDA : -1.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NXGL NexGel Inc NXGL
60 GF Score
Price $0.44
GF Value $4.41
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is NexGel Debt-to-EBITDA?

NexGel NXGL +0.21% 60 Debt-to-EBITDA is -1.63 as of Mar. 2026. GuruFocus rates NXGL with a GF Score™ of 60/100 and a GF Value™ of $4.41 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, NexGel ranks worse than 213675% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

NexGel's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.48 Mil. NexGel's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $3.80 Mil. NexGel's annualized EBITDA for the quarter that ended in Mar. 2026 was $-2.63 Mil. NexGel's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was -1.63.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NexGel's Debt-to-EBITDA or its related term are showing as below:

NXGL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.96   Med: -1.03   Max: -0.49
Current: -1.82

During the past 10 years, the highest Debt-to-EBITDA Ratio of NexGel was -0.49. The lowest was -1.96. And the median was -1.03.

NXGL's Debt-to-EBITDA is ranked worse than
100% of 468 companies
in the Medical Devices & Instruments industry
Industry Median: 1.585 vs NXGL: -1.82

NexGel  (NAS:NXGL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NexGel Debt-to-EBITDA Related Terms


NexGel Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for NexGel's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexGel Debt-to-EBITDA Chart

NexGel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.96 -0.67 -1.03 -1.04 -1.46

NexGel Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.41 -1.17 -1.30 -1.48 -1.63

NXGL vs LUCY, CBSC, RSCF: Debt-to-EBITDA Comparison

For the Medical Instruments & Supplies subindustry, NexGel's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexGel Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NexGel's Debt-to-EBITDA falls into.


NXGL
60GF Score
NexGel Inc NXGL
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexGel Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NexGel's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.474 + 2.614) / -2.119
=-1.46

NexGel's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.484 + 3.802) / -2.628
=-1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -1.63 mean?
NexGel (NXGL) has a Debt-to-EBITDA of -1.63 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NexGel. According to the industry distribution chart, NexGel ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is NexGel's Debt-to-EBITDA too high?
NexGel's current Debt-to-EBITDA is -1.63. Based on the distribution chart, NexGel ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NexGel has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NexGel's Debt-to-EBITDA compare to LUCY and CBSC?
According to the Medical Devices & Instruments industry distribution chart, NexGel ranks #999999 out of 468 companies for Debt-to-EBITDA. This places NexGel in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NexGel. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexGel's current Debt-to-EBITDA is -1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexGel stock overvalued right now?
Based on GuruFocus' analysis, NexGel (NXGL) is currently considered Possible Value Trap. The stock's GF Value™ is $4.41, compared to a current price of $0.44 — trading 90% below its estimated fair value. The current Debt-to-EBITDA is -1.63. NexGel's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NexGel (NXGL), the current Debt-to-EBITDA is -1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexGel (NXGL) Overvalued in 2026?

Based on GuruFocus' analysis, NexGel stock appears to be undervalued. The current stock price of $0.44 is trading 90% below its estimated GF Value™ of $4.41. GuruFocus considers NexGel to be Possible Value Trap.

Key valuation signals for NXGL:

  • Debt-to-EBITDA: -1.63
  • GF Value™: $4.41 vs. price of $0.44 (90% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the NXGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NexGel Business Description

Address 2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
60GF Score

Get the complete analysis for NXGL

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$4.41
GF Value